Refining dual-energy x-ray absorptiometry data to predict mortality among cirrhotic outpatients: A retrospective study

Autor(es)

Amaral Santos, Livia Alves ^[1] ; Lima, Talles Bazeia ^[1] ; Qi, Xingshun ^[2] ; Rupp de Paiva, Sergio Alberto ^[3] ; Romeiro, Fernando Gomes ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Paulista, Fac Med Botucatu, Dept Internal Med, Gastroenterol Div, Sao Paulo - Brazil

^[2] Gen Hosp Northern Theater Command, Dept Gastroenterol, Gen Hosp Shenyang Mil Area, Shenyang - Peoples R China

^[3] Univ Estadual Paulista, Fac Med Botucatu, Dept Internal Med, Nutrol Div, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: NUTRITION; v. 85, MAY 2021.
• Citações Web of Science: 1

Resumo

Objective: The aim of this study was to compare the effects of muscle wasting according to measures obtained by different limb muscle mass indexes, to find the best mortality predictor among outpatients with cirrhosis. Methods: Patients with liver cirrhosis (N = 210) were submitted to dual-energy x-ray absorptiometry (DXA). Appendicular muscle mass (AMM), AMM index (AMMI), upper limb muscle mass (ULMM), and ULMM index (ULMMI) were calculated. The Model for End-Stage Liver Disease, anthropometric measures, and the presence of ascites and edema were also registered. Multiple logistic regressions were performed to determine mortality predictors; the area under the receiver operating characteristic curve was used to establish the best cutoff point to predict mortality. Results: The mean follow-up duration was 49 \& sect; 15.59 mo. ULMM and ULMMI were clearly associated with mortality (P = 0.007 and 0.001, respectively), whereas AMM and AMMI were not. After calculating the cutoff points for men and women, the presence of a depleted ULMMI as a categorical variable was associated with a mortality risk 2.5 times higher. Conclusions: The results suggest that using ULMMI is better than AMMI for predicting mortality of outpatients with cirrhosis, thus offering a better measure to detect muscle wasting in this population using DXA. (c) 2020 Elsevier Inc. All rights reserved. (AU)

• Processo FAPESP: 17/25592-9 - Resposta objetiva tumoral, perfil de segurança e taxas de sobrevida de pacientes com cirrose e carcinoma hepatocelular de estadiamento intermediário submetidos a Radioembolização com 131I-Lipiodol versus Quimioembolização arterial
• Beneficiário: Fernando Gomes Romeiro
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/22572-9 - Resposta ao tratamento da osteoporose e da osteopenia em portadores de cirrose hepática
• Beneficiário: Lívia Alves Amaral Santos
• Modalidade de apoio: Bolsas no Brasil - Doutorado